Literature DB >> 19687318

Therapy-related myeloid neoplasms.

Magdalena Czader1, Attilio Orazi.   

Abstract

Session 5 of 2007 Workshop of the Society for Hematopathology/European Association for Haematopathology focused on therapy-related myeloid neoplasms. This report discusses the diversity and relevance of clinical, pathologic, and genetic features and provides an update on the pathogenesis of these disorders. We highlight common diagnostic issues such as the differentiation between therapy-related myelodysplastic syndrome and therapy-related acute erythroid leukemia. As similar therapeutic interventions are frequently considered for patients with either of these diagnoses, in the current World Health Organization classification, regardless of morphologic presentation, therapy-related myeloid neoplasms are considered together as a unique clinicopathologic syndrome of therapy-related myelodysplastic syndrome/acute myeloid leukemia. Nevertheless, recognition of the diverse morphologic features is crucial as bone marrow morphologic examination remains the first and important step of patient evaluation. We also present examples of therapy-related acute myeloid leukemias with recurrent cytogenetic abnormalities. In these cases, the precise classification is clinically important because it is associated with distinct clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687318     DOI: 10.1309/AJCPD85MCOHHCOMQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.

Authors:  Yiming Chen; Zeev Estrov; Sherry Pierce; Wei Qiao; Gautam Borthakur; Farhad Ravandi; Tapan Kadia; Mark Brandt; Susan O'Brien; Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Miloslav Beran
Journal:  Leuk Lymphoma       Date:  2014-08-13

2.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Authors:  Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia
Journal:  Blood Adv       Date:  2017-07-19

3.  Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: a case report.

Authors:  Ying-Cheng Zhang; Yu-Qi Zhou; Bing Yan; Jun Shi; Li-Juan Xiu; Yu-Wei Sun; Xuan Liu; Zhi-Feng Qin; Pin-Kang Wei; Yong-Jin Li
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

Authors:  Lindsay M Morton; Graça M Dores; Margaret A Tucker; Clara J Kim; Kenan Onel; Ethel S Gilbert; Joseph F Fraumeni; Rochelle E Curtis
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

5.  Racial and ethnic differences in risk of second primary cancers among breast cancer survivors.

Authors:  Gregory S Calip; Ernest H Law; Naomi Y Ko
Journal:  Breast Cancer Res Treat       Date:  2015-05-27       Impact factor: 4.872

Review 6.  Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.

Authors:  Astrid Wintering; Stephen Smith; Beng Fuh; Arun Rangaswami; Gary Dahl; May Chien; Tanja A Gruber; Jinjun Dang; Loretta S Li; Alicia Lenzen; Stephanie Savelli; Christopher C Dvorak; Anurag K Agrawal; Elliot Stieglitz
Journal:  Pediatr Blood Cancer       Date:  2021-12-22       Impact factor: 3.167

7.  Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Authors:  Sa A Wang; Keyur P Patel; Olga Pozdnyakova; Jie Peng; Zhuang Zuo; Paola Dal Cin; David P Steensma; Robert P Hasserjian
Journal:  Mod Pathol       Date:  2016-07-15       Impact factor: 7.842

8.  Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

Authors:  Koji Sasaki; Elias Jabbour; Jorge Cortes; Tapan Kadia; Guillermo Garcia-Manero; Gautam Borthakur; Preetesh Jain; Sherry Pierce; Naval Daver; Koichi Takahashi; Susan O'Brien; Hagop Kantarjian; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08-10

9.  Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.

Authors:  Deniz Peker; Vishwas Parekh; Ravikumar Paluri; Taylor Deal; Uma Borate; Antonio Di Stasi; Shuko Harada; Emmanuel Agosto Arroyo; Vishnu Reddy
Journal:  Int J Hematol       Date:  2014-09-11       Impact factor: 2.490

10.  Attenuated DNA damage repair delays therapy-related myeloid neoplasms in a mouse model.

Authors:  Kit I Tong; Kazushige Ota; Akiyoshi Komuro; Takeshi Ueda; Akihiko Ito; C Anne Koch; Hitoshi Okada
Journal:  Cell Death Dis       Date:  2016-10-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.